Risks of Clinical Trials: What Participants Should Know Before Enrolling

Clinical trials produce the evidence that drives medical progress, but taking part involves real risks that potential volunteers should understand before enrolling. Most trial participants have uneventful experiences, yet adverse events do occur, and the risk profile varies significantly by phase, condition, and individual factors. Understanding the actual risks of clinical trials — separating realistic concerns from overblown fears — is essential for informed decision-making. This guide covers the categories of risk, how trials work to minimize them, the protections that exist for participants, the questions worth asking, and how to weigh whether a specific trial’s balance of risk and potential benefit is right for you. It is general education, not medical advice; discuss any specific trial with your own doctor.

Categories of Risk in Clinical Trials

Trial risks fall into several categories:

Physical risks from the experimental treatment: Side effects, adverse reactions, and unforeseen complications from the drugs, devices, or procedures being tested. These vary enormously by phase — early trials of a novel drug carry more uncertainty about safety than later trials of a treatment with an established safety profile.

Risks from study procedures: Blood draws, biopsies, imaging with contrast, lumbar punctures, and other procedures each carry their own small risks, separate from the experimental treatment itself. Most have low complication rates, but none are entirely risk-free.

The chance of receiving a placebo — or that the treatment may not work: In randomized placebo-controlled trials, some participants are assigned to placebo rather than the experimental treatment. And because the treatment is still being studied, there is no guarantee it will work even for those who receive it. Where an effective standard treatment already exists, being on placebo could mean going without the usual care for a period (see the section on placebo below).

Time and opportunity costs: Trials can require substantial time for visits, testing, and travel, which affects work, family, and access to other options. This is not a medical risk, but it is a real consideration.

Privacy and data considerations: Participation involves sharing detailed medical information that is stored and analyzed. Protections exist, but no data system is absolutely risk-free.

How Trial Phases Affect Risk

Broadly, uncertainty is highest early and decreases as more human safety data accumulates:

Phase 1 (highest uncertainty): First testing in humans means safety data is limited. Doses are typically escalated gradually from very low levels predicted to be safe based on prior research. Serious adverse events are rare but have happened — the TGN1412 trial in 2006 caused severe immune reactions in healthy volunteers, and the BIA 10-2474 trial in 2016 caused serious harm including a death. These events are uncommon, but they illustrate that phase 1 safety is never guaranteed.

Phase 2 (moderate): The treatment has passed initial safety testing but is being studied in people who have the target condition, sometimes for the first time. Side effects can emerge that were not apparent in healthy volunteers.

Phase 3 (lower): There is an established safety profile from earlier phases, and the larger size means rarer side effects can be detected. The risk begins to approximate that of taking the treatment if it is eventually approved.

Phase 4 (lowest): The treatment is already approved with extensive prior human exposure. Phase 4 risk is similar to taking the approved product as prescribed, often with the added benefit of closer monitoring.

What Protections Exist for Participants

Several layers of oversight are designed to minimize and catch problems:

Informed consent: The informed consent process is meant to ensure you understand the potential risks, benefits, and alternatives before enrolling — and that you know you can ask questions and decline. It is a process, not just a signature; the consent form should detail known and potential risks and your right to withdraw at any time, for any reason, without losing your usual medical care.

Institutional Review Boards (IRBs): Independent ethics committees review protocols, consent forms, and ongoing safety information. An IRB can require changes, add monitoring, or halt a study. The HHS Office for Human Research Protections sets the framework these boards work within.

Data and Safety Monitoring Boards (DSMBs): For many larger trials, an independent board reviews safety data periodically and can recommend stopping a study early if a safety signal emerges — or if the treatment proves clearly better or worse than the comparison.

FDA oversight: The FDA reviews trial plans for regulated products and can require changes or place a study on hold if safety concerns arise. Sponsors are required to report serious adverse events promptly, and patterns can trigger protocol changes or termination.

Registration and transparency: Many trials are listed on ClinicalTrials.gov, where you can review eligibility, design, locations, and sometimes results — a useful starting point for research and for questions to bring to the study team.

How to Evaluate the Risks of a Specific Trial

When considering a particular trial, work through the risks systematically:

1. Read the informed consent form carefully — it should describe known and theoretical risks, and it is yours to keep and review at your own pace.
2. Ask the study team about adverse events seen in this trial or related trials, and how side effects would be managed.
3. Ask about the treatment or drug class — established classes have better-understood risk patterns.
4. Consider the phase — an early-phase study carries more uncertainty than a later-phase one.
5. Discuss it with your treating doctor, who can put the trial’s risks in the context of your own condition and options.
6. Ask what happens if you experience side effects — who to contact, what the protocol is, and how care is provided.

Do not rely on recruitment materials alone. The consent form and your conversations with the study team and your own physician are where the real risk picture comes into focus.

The Placebo Question

Some trials randomize participants to a placebo or to the current standard of care rather than to the experimental treatment. Where the experimental treatment might turn out to be more effective than existing options, being assigned to placebo could mean missing that potential benefit during the trial.

Several points help put this in perspective:

• Many trials for serious conditions do not use a pure placebo — they compare the new treatment against the current standard of care, so participants are not left untreated.
• Placebo-controlled designs are most common, and often necessary, where no effective treatment yet exists.
• Some trials offer open-label extensions, allowing participants to access the experimental treatment after the controlled phase.
• Crossover designs let participants receive both placebo and treatment in different periods.

Ask the study team exactly how randomization works in the trial you are considering. For more, see our placebo-controlled trials guide.

Common Adverse Events in Trials

Most adverse events in trials are mild — headache, nausea, fatigue, injection-site reactions, or temporary lab changes — and typically resolve on their own or with simple management. Serious adverse events are less common but do occur, and how often varies widely by treatment type, condition, and the health of the population being studied. Rates cannot be summarized in a single number that applies to every trial, which is exactly why the consent form and the study team’s answers about this specific study matter more than any general figure. In some settings — advanced cancer trials, for example — participants already have serious illness, so events can reflect the underlying disease as much as the treatment.

Risks and Considerations for Specific Groups

Some groups face additional considerations:

Pregnant people: Often excluded from most trials because of potential effects on a pregnancy. Some pregnancy-specific studies exist, with extra protections.

Children: Pediatric trials require additional IRB review, parental permission, and (for older children) the child’s assent, and are heavily regulated.

Older adults: Often have multiple conditions and medications that complicate participation. Some trials specifically study older populations; others may not include them.

People with limited treatment options: Those with advanced or rare disease sometimes face harder risk-benefit decisions. Early-phase trials for people who have exhausted standard options are a well-known example, and are a deeply personal decision worth making with your doctor.

What If Something Goes Wrong

Trial sponsors often cover medical care for serious adverse events directly attributable to the trial treatment or procedures, but the specifics vary by trial and are spelled out in the informed consent. Some trials provide compensation for trial-related injury; others rely on your existing insurance. Coverage for routine medical issues unrelated to the trial generally falls to your normal insurance — a trial does not replace your health coverage.

Read the consent form’s injury and compensation language carefully, and ask the study team directly: what happens if I have a serious adverse event, who pays, and what compensation may be available?

Frequently Asked Questions

Have people died in clinical trials?

Yes, though rarely. Many deaths that occur during trials are from progression of the underlying disease — especially in advanced-cancer studies — rather than from the experimental treatment. Deaths directly caused by a trial treatment are rare but have occurred, particularly in early-phase studies of novel mechanisms.

Can I withdraw once I’ve enrolled?

Yes. You can withdraw from a trial at any time, for any reason, without penalty and without losing your regular medical care. This right is a core part of informed consent. If you are considering withdrawing, it is worth telling the study team so any needed safety follow-up can be arranged.

Can I sue if something goes wrong?

In principle, yes — participants keep their legal rights regardless of what a consent form says. In practice, showing that an adverse event was caused by the trial treatment rather than the underlying condition or other factors can be complex. Consult an attorney for specifics about your situation.

Is it safer to be in a trial than to take an approved drug?

Not necessarily, and it depends on the trial. Trial participants often receive intensive monitoring and rapid response to concerns, which some people value. But early-phase trials carry more uncertainty than taking a well-established approved medication. The right comparison is trial-by-trial, not a blanket rule.

Should I avoid clinical trials?

Not as a general rule. For many people with a relevant condition, a trial can offer access to a potential new treatment, close monitoring, and a contribution to medical progress. The point of this article is not to encourage or discourage participation, but to help you evaluate each specific trial on its own risks and benefits, together with your doctor.

The bottom line: the risks of clinical trials are real but generally manageable, and they are matched by meaningful protections — informed consent, IRBs, safety monitoring, FDA oversight, and your right to withdraw at any time. Early-phase trials carry the most uncertainty; later phases are closer to the risk of an approved treatment. Read the consent form carefully, ask the study team direct questions, look the trial up on ClinicalTrials.gov, and talk it through with your own doctor. The right trial for you is one whose balance of risk and potential benefit makes sense for your situation — not one with zero risk, which does not exist.

Sources

• ClinicalTrials.gov (NIH / National Library of Medicine) — learning about clinical studies, participant considerations, and searching registered trials.
• FDA — clinical trial oversight, informed consent, adverse-event reporting, and participant protections.
• NIH — informed consent and questions to ask before deciding to join a study.
• HHS Office for Human Research Protections (OHRP) — Institutional Review Boards and the framework for protecting human research participants.